Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Related Clinical Trial
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Hizentra® in Inflammatory Neuropathies – pHeNIx Study Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy A Registered Cohort Study of Immune-Mediated Neuropathies Interest of Mycophenolate for CIDP Weaning Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Transcriptome Analysis of the Peripheral Blood in CIDP Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Subcutaneous Immunoglobulin for CIDP Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy MRI in Diagnosing and Monitoring CIDP High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Panzyga in CIDP Administered at Different Infusion Rates Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Brief Title

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Official Title

Multicenter, Prospective, Parallel Group, Open-label, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Brief Summary

      Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory
      Demyelinating Polyradiculoneuropathy (CIDP) Patients
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

CIDP Improvement

Secondary Outcome

 CIDP Relapse

Condition

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

Intervention

Panzyga

Study Arms / Comparison Groups

 Panzyga High Dose
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

September 2021

Completion Date

June 2025

Primary Completion Date

June 2025

Eligibility Criteria

        Inclusion Criteria:

          1. Age ≥2 years and ≤17 years.

          2. Patients with a diagnosis of definite or probable CIDP based on European Neuromuscular
             Center (ENMC) criteria.

          3. Clinical history of functional impairment due to CIDP, corresponding to an mRS score
             ≥2, but ≤5.

          4. Voluntarily given written informed consent (provided by patient's parent or legal
             guardian) or assent (provided by patient, if age-appropriate per Independent Ethics
             Committee [IEC]/Institutional Research Board [IRB] requirements).

        Exclusion Criteria:

          1. Patients with previously diagnosed CIDP who lack any CIDP symptoms.

          2. Patients with a known history of inherited neuropathy or a family history of inherited
             neuropathy.

          3. Patients who have previously failed immunoglobulin therapy for CIDP.

          4. Patients who received intravenous immunoglobulin (IVIG) within 8 weeks prior to the
             Baseline visit (washout phase). However, if a patient has clinical evidence of
             confirmed CIDP relapse during the washout phase (consistent with an in-crease in mRS
             of >1), they are eligible for trial enrolment.

          5. Patients with a history of deep vein thrombosis (DVT) in the past year, or pulmonary
             embolism ever.

          6. Patients on unstable (change in prescribed dose within the last 8 weeks)
             corticosteroids or rituximab use.

          7. Patients with known or suspected hypersensitivity, anaphylaxis or severe systemic
             response to immune-globulins, blood or plasma derived products, or any component of
             PANZYGA.

          8. Female patients who are breastfeeding, pregnant, or planning to become pregnant, or
             are unwilling to use an effective birth control method while on the study (acceptable
             methods of birth control for this study include: intrauterine device [IUD], hormonal
             contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical
             cap).

          9. Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C
             virus (HCV) infections.

         10. Severe liver and/or kidney disease (alanine aminotransferase [ALT] > 3 × upper limit
             of normal [ULN]; aspartate aminotransferase [AST] > 3 × ULN; and/or creatinine levels
             >44 μmol/L for children ages 2-3 years, >62 μmol/L for children ages 4-10, and >89
             μmol/L for children ages 11-17 years.

         11. Known immunoglobulin (IgA) deficiency and antibodies against IgA.

         12. History of alcohol or drug abuse in the previous year, as per Investigator's opin-ion.

         13. Unable or unwilling to comply with the study protocol.

         14. Receipt of any other investigational medicinal product (IMP) within 3 months be-fore
             study entry.

         15. Any other condition(s) that, in the Investigator's opinion, makes it undesirable for
             the patient to participate in the study or may interfere with protocol compliance.
      

Gender

All

Ages

2 Years - 17 Years

Accepts Healthy Volunteers

No

Contacts

, 866-337-1868, [email protected]



Administrative Informations


NCT ID

NCT04929236

Organization ID

NGAM-11


Responsible Party

Sponsor

Study Sponsor

Octapharma


Study Sponsor

, , 


Verification Date

June 2021